Loading organizations...
§ Private Profile · Lausanne, Vaud, Switzerland
Develops implantable directional Deep Brain Stimulation (DBS) systems for Parkinson's disease and other neurological conditions.
Aleva Neurotherapeutics is a Lausanne, Switzerland-based medical device company developing implantable deep brain stimulation systems for neurological conditions like Parkinson's disease and essential tremor. The organization utilizes micro-electromechanical systems technology to create directional neurostimulation devices that improve therapy efficacy and reduce side effects. The enterprise has raised over $50 million in total venture funding, including a $13 million Series E financing, and invested approximately $60 million into product development by 2021. Its clinical trials and commercialization efforts are backed by institutional investors including BioMedPartners, BB Biotech Ventures, Banexi Ventures, and Integer Holdings Corporation. The company secured CE Mark approval for its flagship directDBS system in 2020 to enable European commercialization. Aleva Neurotherapeutics was founded in 2008 as a spin-off from the Swiss Federal Institute of Technology by André Mercanzini, Renaud de Guibert, Alain C. Bertsch, and Philippe Renaud.
Aleva Neurotherapeutics has raised $73.2M across 6 funding rounds.
Aleva Neurotherapeutics has raised $73.2M in total across 6 funding rounds.
Aleva Neurotherapeutics has raised $73.2M across 6 funding rounds. Most recently, it raised $8.0M Series E in December 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 16, 2019 | $8M Series E | — | — | Announced |
| Oct 4, 2017 | $13M Series D | Forrestal Capital | — | Announced |
| May 27, 2016 | $18M Series C | Anthony Borowicz | Banexi Ventures Partners, BB Biotech Ventures, BioMedPartners, Forrestal Capital, Initiative Capital Romandie, Kinled Holding | Announced |
| Sep 4, 2015 | $16.1M Venture Round | — | Banexi Ventures Partners, BB Biotech Ventures, BioMedPartners, Initiative Capital Romandie | Announced |
| Apr 10, 2012 | $4.3M Series B | Sophie Pierrin Lepinard | BB Biotech Ventures, BioMedPartners, Initiative Capital Romandie | Announced |
| Aug 31, 2011 | $13.7M Series A | Juergen Eckhardt, Markus Hosang | Initiative Capital Romandie | Announced |
Aleva Neurotherapeutics has raised $73.2M in total across 6 funding rounds.
Aleva Neurotherapeutics's investors include Forrestal Capital, Anthony Borowicz, Banexi Ventures Partners, BB Biotech Ventures, BioMedPartners, Initiative Capital Romandie, Kinled Holding, Sophie PIERRIN LEPINARD, Juergen Eckhardt, Markus Hosang.